dr. ritchie on immunological recovery with venetoclax and ibrutinib in mcl
Published 4 years ago • 342 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
3:06
durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
-
1:26
dr. eyre discusses venetoclax monotherapy in mcl
-
2:00
ibrutinib in mantle cell lymphoma - an update
-
1:30
final results of the aim study of ibrutinib and venetoclax in mantle cell lymphoma
-
3:27
venetoclax: an unmet need in r/r mantle cell lymphoma after btk inhibitors
-
1:21
novel approaches to harnessing the immune system in lymphoma
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
2:00
preliminary results of the aim trial of ibrutinib and venetoclax in mantle cell lymphoma
-
2:23
phase i trial of nivolumab shows significant benefit for hodgkin's lymphoma, mayo clinic
-
2:50
venetoclax, lenalidomide rituximab: a chemotherapy-free regimen for previously untreated mcl
-
3:45
real-world outcomes of brexu-cel in patients with r/r mcl
-
1:34
the success of ibrutinib in treating mantle cell lymphoma (mcl)
-
1:46
philemon trial: ibrutinib, lenalidomide and rituximab in r/r mcl
-
1:05
covalent-101: bmf-219 in patients with r/r aml, dlbcl & multiple myeloma
-
3:01
treating indolent and mantle cell lymphoma: results of the bright 5 year follow up study
-
2:09
recent investigational advances in mantle cell lymphoma treatment
-
2:31
relevance trial analysis: investigating the impact of lymphocyte/monocyte ratio on patient outcomes